1. Home
  2. STRO vs BMEA Comparison

STRO vs BMEA Comparison

Compare STRO & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STRO
  • BMEA
  • Stock Information
  • Founded
  • STRO 2003
  • BMEA 2017
  • Country
  • STRO United States
  • BMEA United States
  • Employees
  • STRO N/A
  • BMEA N/A
  • Industry
  • STRO Biotechnology: Biological Products (No Diagnostic Substances)
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • STRO Health Care
  • BMEA Health Care
  • Exchange
  • STRO Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • STRO 292.6M
  • BMEA 275.6M
  • IPO Year
  • STRO 2018
  • BMEA 2021
  • Fundamental
  • Price
  • STRO $4.38
  • BMEA $8.18
  • Analyst Decision
  • STRO Strong Buy
  • BMEA Buy
  • Analyst Count
  • STRO 7
  • BMEA 13
  • Target Price
  • STRO $12.14
  • BMEA $37.25
  • AVG Volume (30 Days)
  • STRO 502.2K
  • BMEA 805.0K
  • Earning Date
  • STRO 11-19-2024
  • BMEA 10-29-2024
  • Dividend Yield
  • STRO N/A
  • BMEA N/A
  • EPS Growth
  • STRO N/A
  • BMEA N/A
  • EPS
  • STRO N/A
  • BMEA N/A
  • Revenue
  • STRO $169,359,000.00
  • BMEA N/A
  • Revenue This Year
  • STRO N/A
  • BMEA N/A
  • Revenue Next Year
  • STRO N/A
  • BMEA N/A
  • P/E Ratio
  • STRO N/A
  • BMEA N/A
  • Revenue Growth
  • STRO 197.83
  • BMEA N/A
  • 52 Week Low
  • STRO $2.01
  • BMEA $3.61
  • 52 Week High
  • STRO $6.13
  • BMEA $22.74
  • Technical
  • Relative Strength Index (RSI)
  • STRO 68.55
  • BMEA 32.99
  • Support Level
  • STRO $3.22
  • BMEA $8.60
  • Resistance Level
  • STRO $3.74
  • BMEA $9.34
  • Average True Range (ATR)
  • STRO 0.26
  • BMEA 0.81
  • MACD
  • STRO 0.10
  • BMEA -0.45
  • Stochastic Oscillator
  • STRO 93.55
  • BMEA 3.11

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Share on Social Networks: